Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies

在华盛顿特区大都市的艾滋病毒流行 (S/HE) 中生存 - 通过队列研究增进知识

基本信息

批准号：
10219632
负责人：
SEBLE G KASSAYE
金额：
$ 5.45万
依托单位：
GEORGETOWN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10219632
关键词：
Address Adolescent Adult Affect Age Aging Anti-Retroviral Agents Area Behavioral Behavioral Research Biological Factors Biological Markers Blood Vessels Capital Cardiovascular Diseases Chronic Cohort Studies Collaborations Communities Complex Continuity of Patient Care Death Rate Diagnosis Disease Disease Outcome District of Columbia Dyslipidemias Enrollment Ensure Epidemic Failure Funding Geographic Factor Geography Goals HIV HIV Infections Health Health Personnel Healthcare Systems Hearing problem Immunologics Impairment Individual Intervention Knowledge Lead Leadership Life Malignant Neoplasms Maryland Measures Mediating Mental disorders Metabolic Morbidity - disease rate Neurocognitive Deficit Newly Diagnosed Outcome Participant Play Population Positioning Attribute Prevalence Prevention Prevention Guidelines Preventive screening Protocols documentation Research Research Personnel Risk Risk Factors Role Savings Science Site Socioeconomic Status Surveys The Multicenter AIDS Cohort Study Translating Treatment Effectiveness Treatment Protocols United States Viral Virus Washington Woman Women’s Interagency HIV Study aged antiretroviral therapy base behavioral study cardiovascular disorder risk cardiovascular risk factor cohort comorbidity coping data acquisition effective therapy equilibration disorder glucose metabolism health seeking behavior healthy aging high risk immune activation improved innovation lifetime risk male men men&apos s group metropolitan microbiome mortality novel optimal treatments outcome prediction pre-clinical prevent protocol development psychosocial racial difference recruit research study resilience service delivery side effect social social determinants success tool transmission process treatment adherence treatment guidelines uptake virology

项目摘要

ABSTRACT About 1.1 million people are living with HIV (PLWH) in the US, with an estimated 39,782 individuals newly diagnosed with HIV in 2016. The Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) are two of the longest standing HIV cohort studies in the United States. Established in 1984 and 1993, respectively, these US-based cohorts currently follow 2,235 men and 2,304 women living with HIV, alongside high-risk but uninfected controls. HIV is at epidemic proportions in the nation’s capital, with overall HIV prevalence of 1.9% among the District of Columbia (DC) adult and adolescent residents. Approximately 3.7% of DC residents aged 40 to 49 years and 5.2% of residents aged 50 to 59 years are living with HIV. The highest life time risk of acquiring HIV in the U.S. is highest in DC with an estimated 1 in 17 individuals anticipated to acquire HIV in their lifetime, followed by 1 in 56 risk among the neighboring Maryland residents. Continuing to follow the women we have recruited and expanding our cohort to include a representative group of men and women is imperative in this region with epidemic levels of HIV. Our research will be focused on understanding the behavioral and social determinants that contribute to long term treatment success and failure, with a focus on identifying key resilience factors that may translate into innovative interventions to achieve the global goals of the HIV care continuum, to improve treatment uptake and viral suppression to decrease morbidity and mortality. We have four aims to achieve our goals. (1) To continue our strong collaborative relationship with the national MACS/WIHS CCS in protocol development, implementation, participant enrollment, retention, data acquisition, and sub-study participation; (2) To lead the CCS-wide effort to understand the psychosocial and behavioral determinants that contributes to treatment adherence, virologic suppression, and healthy coping among PLWH in the US; (3) To determine the effectiveness of treatment and prevention guidelines and identify disparities in service delivery for common morbidities with high associated mortality; and (4) To explore HIV, aging, and associated co-morbidities, including the role of microvascular/vascular function, the microbiome, neurocognitive decline in the context of contemporary antiretroviral treatment regimens, and hearing and balance disorders among men and women. Our long-term goal is to improve the health of people living with HIV and to help prevent those without HIV from seroconverting.